Curevac Nv Stock Fundamentals
| 5CV Stock | EUR 2.49 0.09 3.75% |
CureVac NV fundamentals help investors to digest information that contributes to CureVac NV's financial success or failures. It also enables traders to predict the movement of CureVac Stock. The fundamental analysis module provides a way to measure CureVac NV's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CureVac NV stock.
CureVac |
CureVac NV Company Current Valuation Analysis
CureVac NV's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current CureVac NV Current Valuation | 792.23 M |
Most of CureVac NV's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CureVac NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, CureVac NV has a Current Valuation of 792.23 M. This is 94.48% lower than that of the Healthcare sector and 82.95% lower than that of the Biotechnology industry. The current valuation for all Germany stocks is 95.23% higher than that of the company.
CureVac NV Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CureVac NV's current stock value. Our valuation model uses many indicators to compare CureVac NV value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CureVac NV competition to find correlations between indicators driving CureVac NV's intrinsic value. More Info.CureVac NV is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CureVac NV's earnings, one of the primary drivers of an investment's value.CureVac Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CureVac NV's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CureVac NV could also be used in its relative valuation, which is a method of valuing CureVac NV by comparing valuation metrics of similar companies.CureVac NV is currently under evaluation in current valuation category among its peers.
CureVac Fundamentals
| Return On Equity | -0.19 | |||
| Return On Asset | -0.34 | |||
| Profit Margin | (1.26) % | |||
| Operating Margin | (7.27) % | |||
| Current Valuation | 792.23 M | |||
| Shares Outstanding | 221.98 M | |||
| Shares Owned By Insiders | 45.68 % | |||
| Shares Owned By Institutions | 19.07 % | |||
| Price To Book | 2.07 X | |||
| Price To Sales | 13.59 X | |||
| Revenue | 102.99 M | |||
| Gross Profit | (135.09 M) | |||
| EBITDA | (386.49 M) | |||
| Net Income | (411.72 M) | |||
| Cash And Equivalents | 1.33 B | |||
| Cash Per Share | 7.34 X | |||
| Total Debt | 55.28 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 5.61 X | |||
| Book Value Per Share | 3.29 X | |||
| Cash Flow From Operations | (733.13 M) | |||
| Earnings Per Share | (0.63) X | |||
| Target Price | 72.97 | |||
| Number Of Employees | 764 | |||
| Beta | 2.93 | |||
| Market Capitalization | 1.85 B | |||
| Total Asset | 1.16 B | |||
| Z Score | 19.8 | |||
| Net Asset | 1.16 B |
About CureVac NV Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CureVac NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CureVac NV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CureVac NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid . The company was founded in 2000 and is headquartered in Tbingen, Germany. CUREVAC N operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 455 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in CureVac Stock
When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CureVac NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in CureVac Stock please use our How to Invest in CureVac NV guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.